The management of Sjögren's syndrome

Nature Clinical Practice Rheumatology

Volumn 2, Issue 5, 2006, Pages 252-261

  Mavragani, Clio P ^a   Moutsopoulos, Niki M ^b   Moutsopoulos, Haralampos M ^c  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Extraglandular manifestation; Management; Sicca manifestation; Sj gren's syndrome; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BICARBONATE; BROMHEXINE; CALCIUM CHANNEL BLOCKING AGENT; CEVIMELINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIQUAFOSOL; ETANERCEPT; HYALURONIC ACID; IMMUNOSUPPRESSIVE AGENT; LUBRICATING AGENT; METHYLCELLULOSE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; NYSTATIN; PILOCARPINE; PNEUMOCOCCUS VACCINE; POTASSIUM; PREDNISOLONE; RITUXIMAB; TAUROURSODEOXYCHOLIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANDROGEN DEFICIENCY; ANTIBODY SCREENING; ARTHRALGIA; ATROPHIC GASTRITIS; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; BLEPHARITIS; CANCER RISK; CELIAC DISEASE; CEREBROVASCULAR ACCIDENT; CORNEA LESION; CORNEA ULCER; CYANOCOBALAMIN DEFICIENCY; DISEASE CLASSIFICATION; DRUG INDUCED HEADACHE; DRY EYE; DYSPAREUNIA; ELECTROSTIMULATION; EYE INFECTION; EYELID DISEASE; FATIGUE; FIBROMYALGIA; FLUSHING; GASTROESOPHAGEAL REFLUX; GLOMERULONEPHRITIS; HEAT TREATMENT; HISTOPATHOLOGY; HUMAN; HYPERCHLOREMIC ACIDOSIS; HYPOKALEMIA; HYPOSALIVATION; HYPOTHYROIDISM; IMMUNIZATION; INFECTION PREVENTION; INTERSTITIAL LUNG DISEASE; INTESTINE CANCER; KERATITIS; KERATOCONJUNCTIVITIS SICCA; KINESIOTHERAPY; LIFESTYLE; LYMPHOMA; MALIGNANT TRANSFORMATION; MEDLINE; MONONEUROPATHY MULTIPLEX; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; MYALGIA; NONHUMAN; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; POLYARTHRITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RAYNAUD PHENOMENON; RESPIRATORY TRACT DISEASE; REST; REVIEW; SCAR FORMATION; SCHIRMER TEST; SEBACEOUS GLAND DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; SJOEGREN SYNDROME; SMALL AIRWAY DISEASE; STREPTOCOCCUS INFECTION; SWEATING; SYSTEMATIC REVIEW; THRUSH; URINARY FREQUENCY; VASCULITIS; XEROSTOMIA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; GASTROINTESTINAL DISEASES; HUMANS; HYALURONIC ACID; MOUTH DISEASES; SJOGREN'S SYNDROME;

EID: 33646464386     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0165     Document Type: Review

References (50)

1. Kassan SS and Moutsopoulos HM (2004) Clinical manifestations and early diagnosis of Sjögren's syndrome. Arch Intern Med 164:1275-1284
2. Vitali C et al. (2002) Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-558
3. Mavragani CP et al. (2000) Sjögren's syndrome: Autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol 123: 46-57
4. Manthorpe R et al. (2000) Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome? Ann Rheum Dis 59:54-60
5. Skopouli FN et al. (2000) Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 29: 296-304
6. Samarkos M and Moutsopoulos HM (2005) Recent advances in the management of ocular complications of Sjögren's syndrome. Curr Allergy Asthma Rep 5: 327-332
7. Kalk WW et al. (2002) Oral and ocular manifestations in Sjögren's syndrome. J Rheumatol 29: 924-930
8. Tauber J et al. (2004) Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 23: 784-792
9. Kalk WW et al. (2002) Parotid sialography for diagnosing Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94: 131-137
10. Porter SR et al. (2004) An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97: 28-46
11. Pedersen AM et al. (2005) Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjögren's syndrome. BMC Clin Pathol 5: 4
12. Hernandez YL and Danils TE (1989) Oral candidiasis in Sjögren's syndrome: Prevalence, clinical correlations, and treatement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 68: 324-329
13. Bootsi EA et al. (2000) Dental and periodontal status of Sjögren's syndrome. J Clin Periodontol 27: 231-235
14. Vissink A et al. (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14: 199-212
15. Ellepola AN and Samaranayake LP (2000) Oral candidal infections and antimycotics. Crit Rev Oral Biol Med 11: 172-198
16. Johnstone PA et al. (2002) Acupuncture for xerostomia: Clinical update. Cancer 94: 1151-1156
17. Haila S et al. (2005) Effects of homeopathic treatment on salivary flow rate and subjective symptoms in patients with oral dryness: A randomized trial. Homeopathy 94: 175-181
18. Vivino FB et al. (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: A randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 159: 174-181
19. Tsifetaki N et al. (2003) Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: A randomised 12 week controlled study. Ann Rheum Dis 62: 1204-1207
20. Fife RS et al. (2002) Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: A randomized trial. Arch Intern Med 162: 1293-1300
21. Petrone D et al. (2002) A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46: 748-754
22. Ono M et al. (2004) Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: A randomized, double-blind clinical study. Am J Ophthalmol 138: 6-17
23. Pillemer SR et al. (2004) Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome. Arthritis Rheum 51: 601-604
24. Moutsopoulos NM and Moutsopoulos HM (2001) Therapy of Sjögren's syndrome. Springer Semin Immunopathol 23: 131-145
25. Roblin X et al. (2004) Celiac disease must be evaluated in patients with Sjögren syndrome. Arch Intern Med 164: 2387
26. Zandbelt MM et al. (2004) Etanercept in the treatment of patients with primary Sjögren's syndrome: A pilot study. J Rheumatol 31: 96-101
27. Manoussakis MN and Moutsopoulos HM (1996) Antimalarials in Sjögren's syndrome - the Greek experience. Lupus 5 (Suppl 1): S28-S30
28. Skopouli FN et al. (1990) Raynaud's phenomenon in primary Sjögren's syndrome. J Rheumatol 17: 618-620
29. Garcia-Carrasco M et al. (2002) Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 29: 726-730
30. Volter F et al. (2004) Esophageal function and Sjögren's syndrome. Dig Dis Sci 49: 248-253
31. Ford CN (2005) Evaluation and management of laryngopharyngeal reflux. JAMA 294: 1534-1540
32. Goules A et al. (2000) Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) 79: 241-249
33. Linardaki G and Moutsopoulos HM (1997) The uncertain role of immuno-suppressive agents in Sjögren's syndrome. Cleve Clin J Med 64: 523-526
34. Matsumoto T et al. (2005) Autoimmune hepatitis in primary Sjögren's syndrome: Pathological study of the livers and labial salivary glands in 17 patients with primary Sjögren's syndrome. Pathol Int 55: 70-76
35. Papiris SA et al. (1999) Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis 58: 61-64
36. Soliotis FC et al. (2004) Central nervous system involvement in Sjögren's syndrome. Ann Rheum Dis 63: 616-620
37. Font J et al. (2003) Pure sensory neuropathy in primary Sjögren's syndrome. Long-term prospective follow-up and review of the literature. J Rheumatol 30: 1552-1557
38. Levy Y et al. (2005) Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann NY Acad Sci 1051: 779-786
39. Voulgarelis M et al. (2004) Combined therapy with rituximab plus cyclophosphamide/ doxorubicin/vincristine/ prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 43: 1050-1053
40. Gottenberg JE et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913-920
41. Pijpe J et al. (2005) Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum 52: 2740-2750
42. Voulgarelis M et al. (2005) Long-term remission of Sjögren's syndrome-associated aggressive B-cell non-Hodgkin's lymphomas following administration of combined B-cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis [doi: 10.1136/ard. 2005.046193]
43. Voulgarelis M et al. (2002) 2-chloro-2′-deoxyadenosine in the treatment of Sjögren's syndrome-associated B cell lymphoproliferation. Arthritis Rheum 46: 2248-2249
44. Hayashi Y et al. (2004) Effective treatment of a mouse model of Sjögren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody. Arthritis Rheum 50: 2903-2910
45. Motegi K et al. (2005) Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2′-deoxycytidine: A possibility for improvement of xerostomia in patients with Sjögren's syndrome. Lab Invest 85: 342-353
46. Kurien BT et al. (2005) Induction of oral tolerance in experimental Sjögren's syndrome autoimmunity. Scand J Immunol 61: 418-425
47. Lodde BM et al. (2006) Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren's syndrome. Ann Rheum Dis 65: 195-200
48. Mavragani CP and Moutsopoulos HM (2005) Immunosuppression and immunomodulation in Sjögren's syndrome - what is the evidence? Does it relieve the sicca symptoms? Aktuelle Rheumatologie 30: 66-70
49. Dawson LJ et al. (2005) Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 44: 449-455
50. Pijpe J et al. (2005) Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren's syndrome and associated MALT lymphoma. Ann Rheum Dis 64: 958-960